Abstract:Background: Prostate carcinoma is a major cause of morbidity and mortality. The MAPK Signaling Pathway plays an important role in multiple tumors, including prostate carcinoma. MAPK signaling is mediated by ERK1/2, JNK and p38 MAPK, which are important in the control of cell proliferation, differentiation and apoptosis. However, relatively little is known about the regulatory mechanism of p38 MAPK in prostate cancers. NOB1 is among the most novel topic in MAPK studies currently. Recent studies found its vital role in tumor metastasis in glioblastoma proliferation, however, its expression profile and its prognostic value in prostate carcinoma have not been investigated. Methods: To determine the relationship between NOB1 and p38 MAPK expressions, a population-based study was conducted for immunohistochemical staining analysis of tumor tissues, in matched malignant and non-malignant prostatectomy samples from 132 PCa patients. Moreover, Western blot analysis and NOB1 interference studies of prostate cancer cell lines. To evaluate the diagnostic and prognostic between NOB1 and p38 MAPK in prostate cancer (PCa) tissue after radical prostatectomy, the hypothesis that prostate cancers with NOB1 expression have distinct clinical, prognostic and molecular attributes was tested. Results: Among 132 prostate cancers, NOB1 expression was detected in 117 (88.7%) tumors by immunohistochemistry. NOB1 and p38 MAPK expression had significant positive correlation with carcinogenesis, tumor progression and patient survival. Immunohistochemically, NOB1 expression in prostate cancer was independently associated with p38 MAPK activation (P=0.0002). Furthermore, p38 MAPK expression was completely suppressed by NOB1 interference in the prostate cancer cell lines DU-145 and PC-3. Conclusions: NOB1 expression status was closely correlated with important histopathologic characteristics and the recurrence and metastasis of prostate carcinomas. These data support a potential link between NOB1 and p38 MAPK, and suggest that NOB1 may identify a subset of prostate cancer patients with a poor prognosis. This study proved that NOB1 in PCa tissue can be used, in combination with traditional clinicopathological factors, as promising diagnostic and prognostic tools.

NO/NOS system in prostate cancer

The role of nitric oxide synthase/ nitric oxide in infection-related cancers: Beyond antimicrobial activity

Endothelial nitric oxide synthase (eNOS)-NO signaling axis functions to promote the growth of prostate cancer stem-like cells

Nitric Oxide Inhibits Hetero-adhesion of Cancer Cells to Endothelial Cells: Restraining Circulating Tumor Cells from Initiating Metastatic Cascade

Protein Phosphorylation in Cancer: Role of Nitric Oxide Signaling Pathway

Inflammation and Nitrosative Stress Effects in Ovarian and Prostate Pathology and Carcinogenesis.

The Emerging Roles of Nitric Oxide in Ferroptosis and Pyroptosis of Tumor Cells.

A Potential Target for Developing Agents to Prevent or Treat Highly Aggressive Breast Cancer

Regulation of pleiotropic physiological roles of nitric oxide signaling

Research Advances on Tumor Therapy via Nitric Oxide

Downregulated NOX4 underlies a novel inhibitory role of microRNA‐137 in prostate cancer

Effects of inducible nitric oxide synthase on tumorigenesis and biological characteristics in human oral cancer cell

Nitric Oxide and Pancreatic Cancer Pathogenesis, Prevention, and Treatment

Abstract IA23: "NO Target for Cancer Stem Cells"

The Experimental Comparison of the Expression of Inducible Nitric Oxide Synthase in Normal Prostate,Benign Prostatic Hyperplasia And Prostate Cancer

Targeting the L-arginine-nitric Oxide Pathway for Cancer Treatment.

Unveiling the significance of inducible nitric oxide synthase: its impact on cancer progression and clinical implications

Expression of nitric oxide synthase in human central nervous system tumors

Nitric oxide-based multi-synergistic nanomedicine: an emerging therapeutic for anticancer

Expression And Clinical Significance Of The Nin One Binding Protein And P38 Mapk In Prostate Carcinoma

Recent advances in diverse nanosystems for nitric oxide delivery in cancer therapy